• Response rate after completion of treatment [ Designated as safety issue: No ]
  

• Survival at 2 years [ Designated as safety issue: No ]
  

OBJECTIVES:

• Assess the toxicity and therapeutic efficacy of yttrium Y 90 radiolabeled humanized anti-Tac (HAT) monoclonal antibody in patients with Tac expressing hematologic malignancies.
• Define the pharmacokinetics of indium In 111 and yttrium Y 90 HAT monoclonal antibodies.

OUTLINE: This is a dose escalation study.

Patients are given yttrium Y 90 labeled humanized anti-Tac monoclonal antibody (Y-HAT) according to an escalating dose schedule along with a fixed dose of pentetic acid calcium (Ca-DTPA) and indium In 111 labeled humanized anti-Tac monoclonal antibody (In-HAT). On day 1, Y-HAT and In-HAT are administered IV over 2 hours followed by a 5 hour infusion of Ca-DTPA. Additional 5 hour infusions of Ca-DTPA are given on days 2 and 3. On day 42 the treatment course may be repeated at the same dosage level.

Cohorts of 3 to 6 patients are enrolled at each dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more patients experience dose limiting toxicity. After the MTD is defined the phase II portion of the study begins.

PROJECTED ACCRUAL: Approximately 55 patients will be accrued in phase I and an additional 30 patients in phase II.

DISEASE CHARACTERISTICS:

• Histologically confirmed Hodgkin's lymphoma, non-Hodgkin's lymphoma, or lymphoid leukemia with at least 10% of malignant cells reacting with anti-Tac monoclonal antibody (waived for Hodgkin's lymphoma)

• Must meet the following disease specific criteria:

  • Non-Hodgkin's lymphoma (NHL)

    • Indolent stages II-IV that failed at least one standard therapy and requiring treatment
    • Aggressive NHL that relapsed after standard chemotherapy, and not eligible for or refused salvage chemotherapy or bone marrow transplantation

  • Hodgkin's lymphoma

    • Stages II-IV that relapsed or failed to achieve complete remission after first line chemotherapy, and not eligible for or refused salvage chemotherapy or bone marrow transplantation

  • Cutaneous T-cell lymphoma

    • Stages Ib-III that failed at least one standard therapy
    • Stage IV eligible regardless of prior therapy

  • Peripheral T-cell lymphoma

    • Stages I-IV that relapsed after first line chemotherapy, and not eligible for or refused salvage chemotherapy or bone marrow transplantation

  • Other lymphoid leukemia or lymphoma

    • Failed standard therapy and not eligible for or refused salvage chemotherapy or bone marrow transplantation

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• Karnofsky 50-100%

Life expectancy:

• Greater than 1 month

Hematopoietic:

• Granulocyte count at least 1,200/mm^3
• Platelet count greater than 100,000/mm^3

Hepatic:

• SGOT and SGPT less than 5 times upper limit of normal (ULN)
• Bilirubin less than 3 times ULN

Renal:

• Creatinine less than 2.0 mg/dL OR
• Creatinine clearance greater than 50 mL/min

Cardiovascular:

• No clinical evidence of cardiac failure

Pulmonary:

• No symptomatic pulmonary dysfunction unless due to malignancy

Other:

• Not pregnant or nursing
• Negative pregnancy test
• HIV negative
• No active second primary malignancy other than basal cell skin cancer
• No symptomatic disease due to CNS involvement

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No chronic anticoagulant therapy
• No prior bone marrow or stem cell transplantation

Chemotherapy:

• At least 3 weeks since prior chemotherapy
• No concurrent chemotherapy

Endocrine therapy:

• Corticosteroids allowed if dose is stable for at least 3 weeks

Radiotherapy:

• At least 3 weeks since prior radiotherapy
• No concurrent radiotherapy

Surgery:

• Not specified